Median overall survival is the same for both malignancies, study results show.

Atezolizumab shows similar efficacy in upper tract urothelial carcinoma and standard bladder cancer

As practices reboot, urologists consider leaner staffs and operations.

Pandemic exacts economic toll on urology practices

Mitomycin sees the largest annual growth in spending per dose over the past 5 years, Robert A. Dowling, MD, reports.

Denosumab tops spending for common urology Part B drugs

Three codes are available for prostate biopsy, but only one is typically used for perineal biopsy, according to Jonathan Rubenstein, MD, and Mark Painter.

Vol 48 No 6